On November 10, 2026, Beam Therapeutics announced that its base-editing therapy risto-cel achieved freedom from severe pain crises in a 31-patient pivotal trial for sickle cell disease. Base editing alters individual DNA nucleotides without double-stranded cuts. Beam plans an FDA submission by year-end 2026, positioning risto-cel as the first base-editing therapy to seek regulatory approval against market rivals Casgevy and Lyfgenia.
Phase 1/2 trial results for risto-cel
- ▪In the trial of risto-cel for sickle cell disease, 31 patients completed treatment and 12 months of follow-up as of October 20, 2026
- ▪Beam Therapeutics announced its base-editing treatment ristoglogene autogetemcel met its primary endpoint of freedom from severe vaso-occlusive crises
FDA approval plans for risto-cel
- ▪An FDA application for risto-cel would represent the first regulatory submission for a base-editing therapeutic technology
- ▪Beam Therapeutics plans to submit an approval application for risto-cel to the U.S. Food and Drug Administration as early as the end of 2026
Mechanism and manufacturing of risto-cel
- ▪Base editing precisely changes individual nucleotides in a DNA sequence without cutting through DNA, unlike older CRISPR approaches
- ▪Risto-cel works by re-engineering patients' extracted cells to switch on production of fetal hemoglobin before transplanting them back into the patient's bone marrow
- ▪RBC Capital Markets analysts reported that risto-cel offers a shorter manufacturing process and requires fewer mobilization treatment cycles compared to existing genetic therapies
Competitive landscape and commercial challenges
- ▪Lyfgenia developer Genetix Biotherapeutics sold itself after encountering difficulties commercializing its gene therapy portfolio
- ▪If approved, risto-cel would enter a sickle cell treatment market that includes approved genetic therapies Casgevy and Lyfgenia, alongside hydroxyurea, l-glutamine, blood transfusions, and stem cell transplants
- ▪Vertex Pharmaceuticals generated $116 million in Casgevy sales from 64 patients in 2025 and $219 million through the first nine months of 2026
Story comments
Loading comments…